All News
FDA Approves Romosuzumab (Evenity) for High Risk Osteoporosis
The US Food and Drug Administration today approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of osteoporotic fracture, including those with a history of osteoporotic fracture or multiple risk factors for fracture, or those who have failed or are intoler
Read Article
Chronic Kidney Disease Augments Gout Risks
A population based cohort analysis shows that patients with incident gout and chronic kidney disease (CKD) have far worse outcomes than those without CKD.
Read Article
ACR Position Statements on Drug Pricing and Step Therapy
The American College of Rheumatology Committee on Rheumatologic Care has released new drug pricing and step therapy position statements that they hope legislators will consider as they continue to explore policy and regulatory options to make drugs more affordable and accessible.
Read Article
Increasing Prevalence and Consequences of Interstitial Lung Disease in RA
Interstitial lung disease (ILD) has been a hot topic in numerous journals recently with reports of increasing incidence and links to disease activity.
Read Article
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Links:
Dr. John Cush RheumNow ( View Tweet)
Madelaine Feldman MattieRheumMD ( View Tweet)
Dr. John Cush RheumNow ( View Tweet)
